IntraBio

Company snapshot

IntraBio Inc is a pharmaceutical company located in Austin, Texas focusing on drug discovery, development, and commercialization related to rare and common neurodegenerative and neurodevelopmental diseases.

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for IntraBio. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for IntraBio.

1. Jun 5, 2026 Clinical update

   Granules for oral suspension, N-Acetyl-L-Leucine — Phase 3

2. Jun 5, 2026 Clinical update

   granules for suspension, N-Acetyl-L-Leucine — Phase 3

3. Jun 5, 2026 Clinical update

   N-Acetyl-L-Leucine, granules for suspension — Phase 3

View all clinical trial activity →

• What is IntraBio?

  Intrabio Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include CACNA1A Disorders, Niemann-Pick disease type C, Ataxia Telangiectasia. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from

• Is IntraBio publicly traded?

  IntraBio appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does IntraBio develop or market?

  We link 3 drug profile(s) where IntraBio is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/intrabio-ireland-limited#company-drugs.

• What are the latest developments for IntraBio?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does IntraBio focus on?

  IntraBio focuses on CACNA1A Disorders, Niemann-Pick disease type C, Ataxia Telangiectasia based on our analysis of their pipeline programs and drug development activities.